307 related articles for article (PubMed ID: 31400577)
41. Motor unit number index (MUNIX) in patients with anti-MAG neuropathy.
Fatehi F; Delmont E; Grapperon AM; Salort-Campana E; Sévy A; Verschueren A; Boucraut J; Attarian S
Clin Neurophysiol; 2017 Jul; 128(7):1264-1269. PubMed ID: 28545015
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and tolerability of different brands of intravenous immunoglobulin in the maintenance treatment of chronic immune-mediated neuropathies.
Gallia F; Balducci C; Nobile-Orazio E
J Peripher Nerv Syst; 2016 Jun; 21(2):82-4. PubMed ID: 26817673
[TBL] [Abstract][Full Text] [Related]
43. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.
Gorson KC; Natarajan N; Ropper AH; Weinstein R
Muscle Nerve; 2007 Jan; 35(1):66-9. PubMed ID: 16967492
[TBL] [Abstract][Full Text] [Related]
44. Motor unit number index correlates with disability in Charcot-Marie-Tooth disease.
Bas J; Delmont E; Fatehi F; Salort-Campana E; Verschueren A; Pouget J; Lefebvre MN; Grapperon AM; Attarian S
Clin Neurophysiol; 2018 Jul; 129(7):1390-1396. PubMed ID: 29729594
[TBL] [Abstract][Full Text] [Related]
45. Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins.
Ritter C; Bobylev I; Lehmann HC
J Neuroinflammation; 2015 Aug; 12():148. PubMed ID: 26268846
[TBL] [Abstract][Full Text] [Related]
46. Diagnosis and treatment response in the asymmetric variant of chronic inflammatory demyelinating polyneuropathy.
Lucke IM; Wieske L; van der Kooi AJ; van Schaik IN; Eftimov F; Verhamme C
J Peripher Nerv Syst; 2019 Jun; 24(2):174-179. PubMed ID: 31090121
[TBL] [Abstract][Full Text] [Related]
47. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop.
Adrichem ME; Eftimov F; van Schaik IN
J Peripher Nerv Syst; 2016 Sep; 21(3):121-7. PubMed ID: 27241239
[TBL] [Abstract][Full Text] [Related]
48. [Clinical and long-term characteristics of the subtypes of chronic inflammatory demyelinating polyneuropathy].
Shimizu F; Nemoto J; Takeshita Y; Maeda T; Koga M; Kanda T
Rinsho Shinkeigaku; 2022 Mar; 62(3):173-177. PubMed ID: 35228460
[TBL] [Abstract][Full Text] [Related]
49. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy.
Mendell JR; Barohn RJ; Freimer ML; Kissel JT; King W; Nagaraja HN; Rice R; Campbell WW; Donofrio PD; Jackson CE; Lewis RA; Shy M; Simpson DM; Parry GJ; Rivner MH; Thornton CA; Bromberg MB; Tandan R; Harati Y; Giuliani MJ;
Neurology; 2001 Feb; 56(4):445-9. PubMed ID: 11222785
[TBL] [Abstract][Full Text] [Related]
50. NK cell markers predict the efficacy of IV immunoglobulins in CIDP.
Mausberg AK; Heininger MK; Meyer Zu Horste G; Cordes S; Fleischer M; Szepanowski F; Kleinschnitz C; Hartung HP; Kieseier BC; Stettner M
Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 33008921
[TBL] [Abstract][Full Text] [Related]
51. Impairment and disability in 20 CIDP patients according to disease activity status.
Panaite PA; Renaud S; Kraftsik R; Steck AJ; Kuntzer T
J Peripher Nerv Syst; 2013 Sep; 18(3):241-6. PubMed ID: 24028192
[TBL] [Abstract][Full Text] [Related]
52. Nerve Ultrasound and Electrophysiology for Therapy Monitoring in Chronic Inflammatory Demyelinating Polyneuropathy.
Kerasnoudis A; Pitarokoili K; Gold R; Yoon MS
J Neuroimaging; 2015; 25(6):931-9. PubMed ID: 26242571
[TBL] [Abstract][Full Text] [Related]
53. Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy.
Kuitwaard K; Fokkink WR; Brusse E; Vrancken AFJE; Eftimov F; Notermans NC; van der Kooi AJ; Merkies ISJ; Jacobs BC; van Doorn PA
J Peripher Nerv Syst; 2017 Dec; 22(4):425-432. PubMed ID: 29092099
[TBL] [Abstract][Full Text] [Related]
54. Different electrophysiological profiles and treatment response in 'typical' and 'atypical' chronic inflammatory demyelinating polyneuropathy.
Kuwabara S; Isose S; Mori M; Mitsuma S; Sawai S; Beppu M; Sekiguchi Y; Misawa S
J Neurol Neurosurg Psychiatry; 2015 Oct; 86(10):1054-9. PubMed ID: 25424435
[TBL] [Abstract][Full Text] [Related]
55. Infusing IVIG through Community Care Access Services in Patients with CIDP.
Katzberg HD; Rasutis V; Bril V
Can J Neurol Sci; 2016 Mar; 43(2):326-8. PubMed ID: 26552493
[No Abstract] [Full Text] [Related]
56. Characteristics and correlates of sensory function in chronic inflammatory demyelinating polyneuropathy.
Rajabally YA; Narasimhan M
J Neurol Sci; 2010 Oct; 297(1-2):11-4. PubMed ID: 20673919
[TBL] [Abstract][Full Text] [Related]
57. Serum neurofilament light chain does not detect self-reported treatment-related fluctuations in chronic inflammatory demyelinating polyneuropathy.
Poser PL; Sajid GS; Beyer L; Hieke A; Schumacher A; Horstkemper L; Karl AS; Grüter T; Sgodzai M; Pitarokoili K; Gerwert K; Gold R; Fisse AL; Gisevius B; Motte J
Eur J Neurol; 2024 Jan; 31(1):e16023. PubMed ID: 37539836
[TBL] [Abstract][Full Text] [Related]
58. The role of IVIg in autoimmune neuropathies: the latest evidence.
Hughes R
J Neurol; 2008 Jul; 255 Suppl 3():7-11. PubMed ID: 18685920
[TBL] [Abstract][Full Text] [Related]
59. Reassessing IVIg therapy in chronic inflammatory demyelinating polyradiculoneuropathy during COVID-19: a chance to verify the need for chronic maintenance therapy.
Romozzi M; Bisogni G; Sabatelli M; Luigetti M
Neurol Sci; 2021 Mar; 42(3):787-789. PubMed ID: 33428052
[TBL] [Abstract][Full Text] [Related]
60. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial.
Hughes RA
Expert Rev Neurother; 2009 Jun; 9(6):789-95. PubMed ID: 19496683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
